447 related articles for article (PubMed ID: 17081985)
1. The mechanisms of PML-nuclear body formation.
Shen TH; Lin HK; Scaglioni PP; Yung TM; Pandolfi PP
Mol Cell; 2006 Nov; 24(3):331-9. PubMed ID: 17081985
[TBL] [Abstract][Full Text] [Related]
2. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
3. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
4. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
6. The SUMO protease SENP6 is a direct regulator of PML nuclear bodies.
Hattersley N; Shen L; Jaffray EG; Hay RT
Mol Biol Cell; 2011 Jan; 22(1):78-90. PubMed ID: 21148299
[TBL] [Abstract][Full Text] [Related]
7. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
8. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.
Sung KS; Lee YA; Kim ET; Lee SR; Ahn JH; Choi CY
Exp Cell Res; 2011 Apr; 317(7):1060-70. PubMed ID: 21192925
[TBL] [Abstract][Full Text] [Related]
9. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
Adamson AL; Kenney S
J Virol; 2001 Mar; 75(5):2388-99. PubMed ID: 11160742
[TBL] [Abstract][Full Text] [Related]
10. PML positively regulates interferon gamma signaling.
El Bougrini J; Dianoux L; Chelbi-Alix MK
Biochimie; 2011 Mar; 93(3):389-98. PubMed ID: 21115099
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
12. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
13. Role of SUMO-1-modified PML in nuclear body formation.
Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
15. Two-step colocalization of MORC3 with PML nuclear bodies.
Mimura Y; Takahashi K; Kawata K; Akazawa T; Inoue N
J Cell Sci; 2010 Jun; 123(Pt 12):2014-24. PubMed ID: 20501696
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies.
Pennella MA; Liu Y; Woo JL; Kim CA; Berk AJ
J Virol; 2010 Dec; 84(23):12210-25. PubMed ID: 20861261
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.
Komura N; Asakawa M; Umezawa K; Segawa K
Exp Cell Res; 2007 Aug; 313(13):2753-65. PubMed ID: 17585903
[TBL] [Abstract][Full Text] [Related]
18. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
[TBL] [Abstract][Full Text] [Related]
19. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
20. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]